Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2761-2769

  Christodoulou, Christos V ^a   Ferry, David R ^a   Fyfe, David W ^a   Young, Annie ^a   Doran, Jayne ^a   Sheehan, T M T ^a   Eliopoulos, Aristides ^a   Hale, Keith ^a   Baumgart, Joachim ^a   Sass, Gretel ^a   Kerr, David J ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; DEXAMETHASONE; GRANISETRON; TITANIUM; TITANOCENE DICHLORIDE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FATIGUE; FEMALE; GOOD CLINICAL PRACTICE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; ULTRAFILTRATION; VOMITING;

EID: 0031927312     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2761     Document Type: Article

References (27)

1. Rosenberg B, Van Camp L, Trosko JE, et al: Platinum compounds: A new class of potent antitumor agents. Nature 222:385-486, 1969
2. Rosenberg B: Platinum coordination complexes in cancer chemotherapy. Naturwiss 60:399-406, 1973
3. Köpf H, Köpf-Maier P: Titanocen-dichlorid - das erste Metallocen mit cancerostatischer Wirksamkeit. Angew Chem Int Ed Engl 18:477-478, 1979
4. Köpf-Maier P, Köpf HZN: Vanadocen-dichlorid - ein weiterers Antitumor-Agens aus der Metallocenreihe. Z Naturforsch 34b:805-807, 1979
5. Köpf-Maier P, Leitner M, Voigtländer R, et al: Molybdenocene-dichlorid als Antitumor-Agens. Z Naturforsch 34c:1174-1176, 1979
6. Köpf-Maier P, Leitner M, Köpf H: Tumor inhibition by metallocenes: Antitumor activity of niobocin and tungstocene dichlorides. J Inorg Nucl Chem 42:1789-1791, 1980
7. Köpf-Maier P, Köpf H, Neuse EW: Ferricenium complexes: A new type of water-soluble antitumor agent. J Cancer Res Clin Oncol 76:336-340, 1984
8. Harstrick A, Schmoll H-J, Sass G, et al: Titanocenedichloride activity in cisplatin and doxorubicin-resistant human ovarian cancer cell lines. Eur J Cancer 29A:1000-1002, 1993
9. Moebus VJ, Stein R, Keiback DG, et al: Antitumour activity of new organometallic compounds in human ovarian cancer cell lines and comparison to paltin derivatives. Anticancer Res 17:815-822, 1997
10. Cao S, Durran FA, Baumgart J, et al: Titanocene dichloride: A new organometallic compound active in vivo against a variety of human tumors with differential sensitivity to doxorubicin and cisplatin. Proc Am Assoc Cancer Res 36:391, 1995 (abstr 2330)
11. Eliopoulos A, Kerr DJ, Herod J, et al: The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and bcl-2. Oncogene 11:1217-1228, 1995
12. Christodoulou CV, Eliopoulos AG, Young LS, et al: Antiproliferative activity and mechanism of action of titanocene dichloride. Br J Cancer 77:2088-2097, 1998
13. Köpf-Maier P, Hesse M, Köpf H: Tumorhemmung durch Metallocene: Wirkung von Titanocen-, Zirconocene- und Halfoncen-dichlorid gegenuber Ehrlich-Aszites-Tumor der Maus. J Cancer Res Clin Oncol 96:43-51, 1980
14. Köpf-Maier P, Köpf H: Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma. Arzneimforsch Drug Res 37:532-534, 1987
15. Köpf-Maier P, Preib F, Marx T, et al: Tumor inhibition by titanocene complexes: Activity against sarcoma 180. Anticancer Res 6:33-38, 1986
16. Köpf-Maier P: Tumor inhibition by titanocene complexes: Influence on xenografted human adenocarcinomas of the gastrointestinal tract. Cancer Chemother Pharmacol 24:23-27, 1989
17. Köpf-Maier P, Moorman A, Köpf H: Activity of titanocene dihalides against human colon carcinoma heterotransplanted to athymic mice. Eur J Cancer Clin Oncol 21:853-857, 1985
18. Köpf-Maier P: Tumor inhibition by titanocene complexes: Influence upon two xenografted human lung carcinomas. J Cancer Res Clin Oncol 113:342-348, 1987
19. Köpf-Maier P, Geralch S: Pattern of toxicity by titanocene dichloride in mice: Blood and urine chemical parameters. J Cancer Res Clin Oncol 111:243-247, 1986
20. 2 on renal structure. Toxicology 38:81-90, 1986
21. Köpf-Maier P, Erkenswick P: Teratogenicity and embryotoxicity of titanocene dichloride in mice. Toxicology 33:171-181, 1984
22. Köpf-Maier P, Geralch S: Pattern of toxicity by titanocene dichloride in mice. Hematologic parameters. Anticancer Res 6: 227-240, 1986
23. Korfel A, Schmoll HJ, Scheulen ME, et al: Clinical phase I and pharmacokinetic study of titanocene dichloride in patients with advanced solid tumors. Proc Am Soc Clin Oncol 38:356, 1996 (abstr 1875)
24. Heinzel G, Woloszczak R, Thomaun P: Topfit 2.0 Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Berlin, Germany, Gustav Fischer, 1993
25. Doppert K: Die chemie der cyclopentadienyltitanium(IV)-verbindungen in wasserigem medium. Naturwissenscaften 77:19-24, 1990
26. Jacobs C, Kalman SM, Tretton M, et al: Renal handling of cis-diamminedichloroplatinum (II). Cancer Treat Rep 64:1223-1228, 1980
27. Harland SJ, Newell DR, Siddick ZH, et al: Pharmacokinetics of cisdiammine-1, 1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 44:1693-1697, 1984